ClinicalTrials.gg
CompletedNCT03010527BE ABLE 2Updated Oct 18, 2022Results posted

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis

A Phase 2 interventional study of Bimekizumab and Placebo in Chronic Plaque Psoriasis, sponsored by UCB Biopharma SRL. Completed at 36 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-18.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
217
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing bimekizumab in Psoriasis — 4 open to participants now, 5 under way, 3 of them phase 3. bimekizumab · Psoriasis.

Enrollment
8th of 20
217 · median 161
Started
2016
with 2 others
Phase 2
6 of 20
1 open now
Registered
3rd of 20
by date
Lead sponsor
13 of 20
UCB Biopharma SRL

Among the 20 studies testing bimekizumab in Psoriasis, this one is the 8th largest by enrollment, is one of 3 that started in 2016, is one of 6 in phase 2, and was the 3rd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

4 of the 20 studies testing bimekizumab in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About bimekizumab

bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing bimekizumab in Psoriasis, or all of them as a file.
02

Study summary

This is a multicenter extension study to assess the long-term safety, tolerability and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis

03

Conditions studied

  • Chronic Plaque Psoriasis

Browse trials for

Keywords

  • Chronic plaque psoriasis
  • Psoriasis
  • Bimekizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has provided
  • Subject completes all dosing requirements in feeder study and completes PS0010 study without meeting any withdrawal criteria
  • Female subjects of and male subjects with a partner of childbearing potential must continue to use an acceptable method of (as detailed in PS0010) for up to 20 weeks after the last dose of study treatment in PS0011

Exclusion criteria

Exclusion Criteria:

  • Subject has previously participated in this study.
  • Female subjects who plan to become pregnant during the study or within 20 weeks following last dose of study medication. Male subjects who are planning a partner pregnancy during the study or within 20 weeks following the last dose
  • Subject has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the subject's ability to participate in this study.
  • Subject must have a negative interferon gamma release assay (IGRA) as measured at Week 8 of PS0010
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
217 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Subjects with a PASI90 response at Week 12 and receiving Placebo in PS0010 entering PS0011 will receive Placebo.

    Other: Placebo

  • Experimental
    Bimekizumab dosing regimen 1

    Subjects with a PASI90 response at Week 12 receiving dosing regimen 1 in PS0010 entering PS0011 will receive the same dosing regimen. Subjects who do not achieve PASI90 response at Week 12 receiving dosing regimen 1 in PS0010 will be assigned to a higher dosing regimen.

    Drug: Bimekizumab

  • Experimental
    Bimekizumab dosing regimen 2

    Subjects with a PASI90 response at Week 12 receiving dosing regimen 2 in PS0010 entering PS0011 will receive the same dosing regimen. Subjects who do not achieve PASI90 response at Week 12 receiving dosing regimen 2 in PS0010 will be assigned to a higher dosing regimen.

    Drug: Bimekizumab

  • Experimental
    Bimekizumab dosing regimen 3

    Subjects that were initially randomized to bimekizumab dosage regimen 3, 4 and 5 in PS0010 will receive bimekizumab dosing regimen 3.

    Drug: Bimekizumab

Interventions

  • Subjects will receive bimekizumab injections every four weeks (Q4W)

    Also known as: UCB4940

  • OtherPlacebo

    Subjects will receive Placebo injections every four weeks (Q4W)

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Treatment

    Treatment-emergent Adverse Events (TEAEs) were defined as those events which started on or after the date of first dose of PS0011 investigational medicinal product (IMP), or events in which severity worsened on or after the date of first dose of PS0011 study medication. The exposure adjusted incidence rate (EAIR) is defined as the number of subjects (n) with a specific AE adjusted for the exposure and was scaled to 100 subject-years: where the numerator is the total number of subjects experiencing the AE and the denominator is the total time at risk scaled to 100 subject-years; that is, the total summation of individual subject-years at risk up to the first occurrence of the AE for subjects with that AE, and the total subject-years at risk for those subjects not experiencing that AE, divided by 100.

    Time frame: From Baseline until Safety Follow-Up Visit (up to Week 64)

Secondary outcomes

  1. Percentage of Participants With Psoriasis Area Severity Index (PASI90) Response Over Time

    The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. It averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale) and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity. PASI90 response is defined to be equal to 1 if the percentage improvement from Baseline in the PASI scores is 90% or greater and 0 if the percentage improvement from Baseline is less than 90%. This Outcome Measure presents results relative to PS0010 Baseline starting at PS0011 Baseline by PS0010 Week 12 response status.

    Time frame: From Baseline during the Treatment Period (up to Week 48)

  2. Percentage of Participants With Investigator´s Global Assessment Response (Clear or Almost Clear With at Least a 2 Category Improvement From Baseline on a 5-point Scale) Over Time

    The Investigator's Global Assessment (IGA) measures the overall severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response is defined as clear (0) or almost clear (1) with at least a two category improvement from Baseline. This Outcome Measure presents results relative to PS0010 Baseline starting at PS0011 Baseline by PS0010 Week 12 response status.

    Time frame: From Baseline during the Treatment Period (up to Week 48)

07

Results

Posted Oct 25, 2021

Participant flow

The study started to enroll participants in December 2016 and concluded in September 2018. Among the 217 participants in PS0011, no participants were assigned to receive placebo.

Participant flow — Overall Study
MilestoneBimekizumab 64 mg Q4WBimekizumab 160 mg Q4WBimekizumab 320 mg Q4W
Started1511191
Completed159275
Not completed01916
Withdrew: Death001
Withdrew: Adverse event042
Withdrew: Protocol violation010
Withdrew: Lost to follow-up021
Withdrew: Withdrawal by subject034
Withdrew: Withdrawal criteria #9046
Withdrew: Withdrawal criteria #12042
Withdrew: Pdili and withdrawal criteria #9010

Outcome measures

PrimaryIncidence of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Treatment

Treatment-emergent Adverse Events (TEAEs) were defined as those events which started on or after the date of first dose of PS0011 investigational medicinal product (IMP), or events in which severity worsened on or after the date of first dose of PS0011 study medication. The exposure adjusted incidence rate (EAIR) is defined as the number of subjects (n) with a specific AE adjusted for the exposure and was scaled to 100 subject-years: where the numerator is the total number of subjects experiencing the AE and the denominator is the total time at risk scaled to 100 subject-years; that is, the total summation of individual subject-years at risk up to the first occurrence of the AE for subjects with that AE, and the total subject-years at risk for those subjects not experiencing that AE, divided by 100.

Time frame:
From Baseline until Safety Follow-Up Visit (up to Week 64)
Reported as:
Number · no. of new events per 100 subject-years
Incidence of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Treatment
no. of new events per 100 subject-yearsBimekizumab 64 mg Q4W (SS)Bimekizumab 160 mg Q4W (SS)Bimekizumab 320 mg Q4W (SS)
Incidence of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Treatment110.68 (53.08 to 203.55)225.26 (182.88 to 274.53)206.82 (162.95 to 258.86)
SecondaryPercentage of Participants With Psoriasis Area Severity Index (PASI90) Response Over Time

The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. It averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale) and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity. PASI90 response is defined to be equal to 1 if the percentage improvement from Baseline in the PASI scores is 90% or greater and 0 if the percentage improvement from Baseline is less than 90%. This Outcome Measure presents results relative to PS0010 Baseline starting at PS0011 Baseline by PS0010 Week 12 response status.

Time frame:
From Baseline during the Treatment Period (up to Week 48)
Reported as:
Number · percentage of participants
Percentage of Participants With Psoriasis Area Severity Index (PASI90) Response Over Time
percentage of participantsBimekizumab 64 mg Q4W/Bimekizumab 64 mg Q4W/R (FAS)Bimekizumab 160 mg Q4W/Bimekizumab 160 mg Q4W/R (FAS)Bimekizumab 320 mg Q4W/Bimekizumab 320 mg Q4W/R (FAS)Bimekizumab 480 mg Q4W/Bimekizumab 320 mg Q4W/R (FAS)Placebo/Bimekizumab 160 mg Q4W/NR (FAS)Bimekizumab 64 mg Q4W/Bimekizumab 160 mg Q4W/NR (FAS)Bimekizumab 160 mg Q4W/Bimekizumab 320 mg Q4W/NR (FAS)Bimekizumab 320 mg Q4W/Bimekizumab 320 mg Q4W/NR (FAS)Bimekizumab 480 mg Q4W/Bimekizumab 320 mg Q4W/NR (FAS)
PS0011 Baseline10010010010000000
Week 410010097.010045.942.142.966.750.0
Week 810096.410010067.673.757.183.350.0
Week 1210096.410096.781.178.964.310062.5
Week 1610092.710096.783.878.964.310062.5
Week 2010089.193.996.789.284.278.683.362.5
Week 2410085.597.096.783.878.971.483.375.0
Week 2893.390.997.096.791.984.271.483.350.0
Week 3210089.197.093.391.973.771.483.350.0
Week 3610085.597.093.391.973.771.466.750.0
Week 4010083.687.986.789.278.971.483.350.0
Week 4410081.887.986.789.278.971.483.350.0
Week 4810080.087.986.791.968.471.466.750.0
SecondaryPercentage of Participants With Investigator´s Global Assessment Response (Clear or Almost Clear With at Least a 2 Category Improvement From Baseline on a 5-point Scale) Over Time

The Investigator's Global Assessment (IGA) measures the overall severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response is defined as clear (0) or almost clear (1) with at least a two category improvement from Baseline. This Outcome Measure presents results relative to PS0010 Baseline starting at PS0011 Baseline by PS0010 Week 12 response status.

Time frame:
From Baseline during the Treatment Period (up to Week 48)
Reported as:
Number · percentage of participants
Percentage of Participants With Investigator´s Global Assessment Response (Clear or Almost Clear With at Least a 2 Category Improvement From Baseline on a 5-point Scale) Over Time
percentage of participantsBimekizumab 64 mg Q4W/Bimekizumab 64 mg Q4W/R (FAS)Bimekizumab 160 mg Q4W/Bimekizumab 160 mg Q4W/R (FAS)Bimekizumab 320 mg Q4W/Bimekizumab 320 mg Q4W/R (FAS)Bimekizumab 480 mg Q4W/Bimekizumab 320 mg Q4W/R (FAS)Placebo/Bimekizumab 160 mg Q4W/NR (FAS)Bimekizumab 64 mg Q4W/Bimekizumab 160 mg Q4W/NR (FAS)Bimekizumab 160 mg Q4W/Bimekizumab 320 mg Q4W/NR (FAS)Bimekizumab 320 mg Q4W/Bimekizumab 320 mg Q4W/NR (FAS)Bimekizumab 480 mg Q4W/Bimekizumab 320 mg Q4W/NR (FAS)
PS0011 Baseline10096.41001005.410.535.750.025.0
Week 410098.297.010056.857.942.966.762.5
Week 810096.497.010075.784.257.183.362.5
Week 1210092.797.096.781.189.564.383.362.5
Week 1610090.997.096.783.878.957.166.762.5
Week 2010085.593.996.789.284.271.466.775.0
Week 2410081.897.093.383.884.264.383.362.5
Week 2893.389.197.093.386.584.271.466.762.5
Week 3210085.593.993.389.278.971.466.750.0
Week 3610081.890.993.386.578.971.466.737.5
Week 4010083.687.986.786.578.971.466.750.0
Week 4410081.887.986.783.878.971.466.750.0
Week 4810078.287.986.789.268.471.466.762.5

Adverse events

Collected over From PS0011 Baseline and up to Safety-Follow Up (SFU) (up to Week 64). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bimekizumab 64 mg Q4W (SS)0/15 (0%)1/15 (6.7%)10/15 (66.7%)
Bimekizumab 160 mg Q4W (SS)0/111 (0%)7/111 (6.3%)56/111 (50.5%)
Bimekizumab 320 mg Q4W (SS)2/91 (2.2%)7/91 (7.7%)51/91 (56%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventBimekizumab 64 mg Q4W (SS)Bimekizumab 160 mg Q4W (SS)Bimekizumab 320 mg Q4W (SS)
Non-cardiac chest painGeneral disorders1/150/1110/91
CataractEye disorders0/150/1111/91
Otitis externa bacterialInfections and infestations0/150/1111/91
Humerus fractureInjury, poisoning and procedural complications0/150/1111/91
Tibia fractureInjury, poisoning and procedural complications0/150/1111/91
Carpal tunnel syndromeNervous system disorders0/150/1111/91
DyspnoeaRespiratory, thoracic and mediastinal disorders0/150/1111/91
Respiratory failureRespiratory, thoracic and mediastinal disorders0/150/1111/91
Abortion inducedSurgical and medical procedures0/150/1111/91
Circulatory collapseVascular disorders0/150/1111/91
Most frequent other events
Showing 10 of 26
Most frequent other events
EventBimekizumab 64 mg Q4W (SS)Bimekizumab 160 mg Q4W (SS)Bimekizumab 320 mg Q4W (SS)
Oral candidiasisInfections and infestations1/1513/11115/91
NasopharyngitisInfections and infestations2/1515/11111/91
Urinary tract infectionInfections and infestations2/151/1111/91
PsoriasisSkin and subcutaneous tissue disorders2/155/1115/91
HypertensionVascular disorders2/158/1114/91
Upper respiratory tract infectionInfections and infestations1/1510/1119/91
External ear inflammationEar and labyrinth disorders1/150/1111/91
DiarrhoeaGastrointestinal disorders1/150/1111/91
FlatulenceGastrointestinal disorders1/150/1110/91
Non-alcoholic fatty liverHepatobiliary disorders1/151/1110/91

Baseline characteristics

Baseline characteristics refer to the Safety Set (SS) which consisted of all participants who received at least 1 dose of the investigational medicinal product (IMP) in PS0011.

Age, Categorical
Age, Categorical(Participants)Bimekizumab 64 mg Q4WBimekizumab 160 mg Q4WBimekizumab 320 mg Q4WTotal Title
<=18 years0123
Between 18 and 65 years1410577196
>=65 years151218
Age, Continuous
Age, Continuous(years)Bimekizumab 64 mg Q4WBimekizumab 160 mg Q4WBimekizumab 320 mg Q4WTotal Title
Mean44.5 ± 14.744.5 ± 12.843.5 ± 14.744.1 ± 13.7
Sex: Female, Male
Sex: Female, Male(Participants)Bimekizumab 64 mg Q4WBimekizumab 160 mg Q4WBimekizumab 320 mg Q4WTotal Title
Female6403177
Male97160140
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Bimekizumab 64 mg Q4WBimekizumab 160 mg Q4WBimekizumab 320 mg Q4WTotal Title
American Indian /Alaskan native0112
Asian111618
Black1012
White139983195
08

Study locations

36 sites
  • Ps0011 708
    Los Angeles, California 90045, United States
  • Ps0011 706
    Washington, District of Columbia 20037, United States
  • Ps0011 704
    West Des Moines, Iowa 50265, United States
  • Ps0011 738
    Wilmington, North Carolina 28405, United States
  • Ps0011 712
    Portland, Oregon 97223, United States
  • Ps0011 733
    Dallas, Texas 75231, United States
  • Ps0011 709
    Houston, Texas 77004, United States
  • Ps0011 702
    Houston, Texas 77598, United States
  • Ps0011 209
    Edmonton, Canada
  • Ps0011 201
    North Bay, Canada
  • Ps0011 206
    Peterborough, Canada
  • Ps0011 214
    Quebec City, Canada
  • Ps0011 203
    Surrey, Canada
  • Ps0011 205
    Waterloo, Canada
  • Ps0011 300
    Ostrava, Czechia
  • Ps0011 303
    Pardubice, Czechia
  • Ps0011 301
    Praha 10, Czechia
  • Ps0011 304
    Praha, Czechia
  • Ps0011 404
    Kecskemet, Hungary
  • Ps0011 400
    Oroshaza, Hungary
  • Ps0011 405
    Szekszard, Hungary
  • Ps0011 504
    Chiyoda-ku, Japan
  • Ps0011 503
    Minatoku, Japan
  • Ps0011 502
    Nagoya, Japan
  • Ps0011 501
    Shinagawa-ku, Japan
  • Ps0011 600
    Bialystok, Poland
  • Ps0011 603
    Bialystok, Poland
  • Ps0011 611
    Bialystok, Poland
  • Ps0011 610
    Gdynia, Poland
  • Ps0011 604
    Kielce, Poland
  • Ps0011 608
    Krakow, Poland
  • Ps0011 605
    Lublin, Poland
  • Ps0011 606
    Lublin, Poland
  • Ps0011 607
    Warszawa, Poland
  • Ps0011 601
    Wroclaw, Poland
  • Ps0011 609
    Wroclaw, Poland
09

References and documents

Publications

  • Blauvelt A, Papp KA, Merola JF, Gottlieb AB, Cross N, Madden C, Wang M, Cioffi C, Griffiths CEM. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. J Am Acad Dermatol. 2020 Nov;83(5):1367-1374. doi: 10.1016/j.jaad.2020.05.105. Epub 2020 May 29. PubMed 32473974 ↗
  • Gordon KB, Langley RG, Warren RB, Okubo Y, Stein Gold L, Merola JF, Peterson L, Wixted K, Cross N, Deherder D, Thaci D. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2022 Jul 1;158(7):735-744. doi: 10.1001/jamadermatol.2022.1185. PubMed 35544084 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Sep 2018, 21 months.

Results were first posted in Oct 2021, 3 years 1 month after primary completion. A results delay was requested in Sep 2019.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 21 months is above that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2017
First posted
Jan 5, 2017
StartActual
Dec 14, 2016
Primary completionActual
Sep 25, 2018
CompletionActual
Sep 25, 2018
Results delay requested
Sep 24, 2019
Results first posted
Oct 25, 2021
Last update
Oct 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03010527
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Jan 5, 2017
Start date
Dec 14, 2016
Primary completion
Sep 25, 2018
Completion
Sep 25, 2018
Results posted
Oct 25, 2021
Last update
Oct 18, 2022

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion